EuroBiotech Report—Sanofi cuts, AZ in Korea, uniQure M&A, U.K. and BerGenBio

Map of Europe

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with the evolving R&D strategies of two Big Pharma companies. Sanofi dropped the biggest news, revealing it is axing 466 French and German employees as part of a retreat from cardiovascular research. AstraZeneca, meanwhile, is looking to South Korea for innovation, outlining plans to spend $630 million in the country over the coming years. Elsewhere, reports emerged that uniQure is the latest gene therapy player to attract buyout bids. A report found distrust is stopping the U.K. healthcare system from collaborating effectively with pharma. BerGenBio shared data on bemcentinib in acute myeloid leukemia. And more. — Nick Taylor
1. Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D 

Sanofi is to cut 466 jobs in France and Germany as part of the reorganization of its R&D group. The job losses are part of a pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies.
2. AstraZeneca commits $630M to Korean drug R&D push
AstraZeneca is set to spend $630 million (€562 million) on R&D in South Korea over the next five years. The commitment is part of a wider agreement between organizations in Korea and Sweden. 

3. UniQure weighs sale after hemophilia gene therapy turnaround: report


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Gene therapy specialist uniQure is considering selling up amid interest from large pharma buyers, according to Bloomberg. The report follows the revitalization of uniQure’s hemophilia B prospect and accompanying triple-digit stock price surge.

4. Distrust is frustrating U.K. NHS-industry cooperation: report

Britain’s National Health Service and pharma industry are failing to collaborate effectively, according to a report involving people on both sides of the divide. The report cites distrust among the barriers that are limiting the number of effective cross-sector collaborations.
5. BerGenBio posts updated data on trial of elderly AML patients

BerGenBio has posted updated data from its phase 2 trial of bemcentinib in acute myeloid leukaemia (AML). The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.
And more articles of note>>

Suggested Articles

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs. 

Dewpoint Therapeutics is teaming up with Bayer on new drugs for a pair of neglected fields: heart disease and women’s health.